• Publications
  • Influence
Complications of craniofacial resection for malignant tumors of the skull base: Report of an International Collaborative Study
This international collaborative report examines a large cohort of patients accumulated from multiple institutions with the aim of identifying patient‐related and tumor‐related predictors of postoperative morbidity and mortality and set a benchmark for future studies.
Craniofacial surgery for malignant skull base tumors
No single center treats enough patients to accumulate significant numbers for meaningful analysis of outcomes after craniofacial surgery (CFS), so a large cohort that was analyzed retrospectively by an International Collaborative Study Group is analyzed.
Craniofacial resection for malignant paranasal sinus tumors: Report of an International Collaborative Study
This International Collaborative study examines a large cohort of patients accumulated from multiple institutions experienced in craniofacial surgery, with the aim of reporting benchmark figures for outcomes and identifying patient‐related and tumor‐related predictors of prognosis after cranioFacial resection (CFR).
Partial laryngectomy in the treatment of radiation‐failure of early glottic carcinoma
This study was undertaken to analyze the functional results, complications, local control rates, and survival in patients undergoing conservation surgery for squamous cell carcinoma (SCC) of the
Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma
Assessing and targeting these molecules are promising strategies to improve the prognosis of unresectable, metastatic or recurrent SDC, and a classification system according to the molecular expression status may be useful to select appropriate therapy.
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma
This study suggests that CAB has equivalent efficacy and less toxicity for patients with AR-positive RM or unresectable LA SGC compared with conventional chemotherapy, which warrants further study.
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
Encouraging efficacy of trastuzumab plus docetaxel therapy in patients with human epidermal growth factor receptor 2-positive SDC is shown, with a manageable toxicity profile.
Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study.
This collaborative study of patients treated at various institutions across the world demonstrates the efficacy of CFR for ENB, and intracranial extension of disease and complete surgical excision were independent prognostic predictors of outcome.